These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 2454354)

  • 21. Carvedilol outclasses the other beta-blockers.
    Cardiovasc J S Afr; 2001; 12(2):120-1. PubMed ID: 11474696
    [No Abstract]   [Full Text] [Related]  

  • 22. Therapeutic benefits and safety of carvedilol in the treatment of renal hypertension. An open, short term study. Carvedilol Renal Hypertension Study Group in Japan.
    Kohno M; Takeda T; Ishii M; Saruta T; Mizuno Y; Yoshimura M; Kubo S; Fukiyama K; Fujishima M
    Drugs; 1988; 36 Suppl 6():129-35. PubMed ID: 2908299
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
    Lund-Johansen P; Omvik P; Nordrehaug JE; White W
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute and long-term hemodynamic effects of carvedilol, a combined beta-adrenoceptor blocking and precapillary vasodilating agent, in hypertensive patients.
    Eggertsen R; Sivertsson R; Andrén L; Hansson L
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S97-100. PubMed ID: 2454378
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
    Abshagen U
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of carvedilol in renal hypertension. A multicenter open trial.
    Takeda T; Kohno M; Ishii M; Kubo S; Saruta T; Mizuno Y; Fukiyama K; Fujishima M; Yoshimura M
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S158-63. PubMed ID: 1974508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of carvedilol in mild to moderate essential hypertension and effects on microalbuminuria: a multicenter, randomized, open-label, controlled study versus atenolol.
    Marchi F; Ciriello G
    Adv Ther; 1995; 12(4):212-21. PubMed ID: 10155349
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Balanced beta--alpha-blocker treatment with carvedilol in mild-moderate arterial hypertension].
    Perocchio M; Gigli G; Barra M; Sacchetti R; Vallebona A; Rosolen GA; Orlandi S
    Minerva Cardioangiol; 1996 Mar; 44(3):115-21. PubMed ID: 8767610
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure.
    Del Sindaco D; Pulignano G; Cioffi G; Tarantini L; Di Lenarda A; De Feo S; Opasich C; Minardi G; Giovannini E; Leggio F
    J Cardiovasc Med (Hagerstown); 2007 Sep; 8(9):675-82. PubMed ID: 17700396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of carvedilol in elderly hypertensive patients.
    Morgan TO; Anderson A; Cripps J; Adam W
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S129-33. PubMed ID: 1974503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Carvedilol for systemic hypertension.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S113-8. PubMed ID: 2454356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Beta-adrenoceptor blockade and vasodilatation in essential hypertension. Hemodynamic studies at rest and during exposure to stress.
    Eggertsen R
    Acta Med Scand Suppl; 1984; 689():1-46. PubMed ID: 6151343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of carvedilol on renal function.
    Dupont AG
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S96-100. PubMed ID: 1974513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).
    Komajda M; Lutiger B; Madeira H; Thygesen K; Bobbio M; Hildebrandt P; Jaarsma W; Riegger G; Rydén L; Scherhag A; Soler-Soler J; Remme WJ;
    Eur J Heart Fail; 2004 Jun; 6(4):467-75. PubMed ID: 15182773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of carvedilol on survival in severe chronic heart failure.
    Packer M; Coats AJ; Fowler MB; Katus HA; Krum H; Mohacsi P; Rouleau JL; Tendera M; Castaigne A; Roecker EB; Schultz MK; DeMets DL;
    N Engl J Med; 2001 May; 344(22):1651-8. PubMed ID: 11386263
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carvedilol therapy in pediatric patients with dilated cardiomyopathy.
    Askari H; Semizel E; Bostan OM; Cil E
    Turk J Pediatr; 2009; 51(1):22-7. PubMed ID: 19378887
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antihypertensive effect of trimepranol, a new beta-blocking agent.
    Jounela AJ; Pentikäinen PJ; Neuvonen PJ
    Int J Clin Pharmacol Biopharm; 1978 Apr; 16(4):183-8. PubMed ID: 25847
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.
    Packer M; Bristow MR; Cohn JN; Colucci WS; Fowler MB; Gilbert EM; Shusterman NH
    N Engl J Med; 1996 May; 334(21):1349-55. PubMed ID: 8614419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial).
    Di Lenarda A; Remme WJ; Charlesworth A; Cleland JG; Lutiger B; Metra M; Komajda M; Torp-Pedersen C; Scherhag A; Swedberg K; Poole-Wilson PA;
    Eur J Heart Fail; 2005 Jun; 7(4):640-9. PubMed ID: 15921806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of carvedilol and metoprolol on blood pressure, blood flow, and vascular resistance.
    Morgan T; Snowden R; Butcher L
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S124-9. PubMed ID: 2454358
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.